Three separate R&D announcements in the past ninety days — from three companies with almost nothing else in common — all point to the same uncomfortable conclusion: Big Pharma is quietly abandoning the diversified portfolio model it spent two decades building, and concentrating firepower into exactly two therapeutic bets. Call it the Great Therapeutic Compression. The industry hasn’t named it yet, but the pattern is unmistakable once you see it.

The signal that made it undeniable came on March 12, when Nature Reviews Drug Discovery published a rare strategic candor moment from Pfizer’s CSO and President of R&D, Chris Boshoff. Oncology. Obesity. More focus, fewer bets. For a company that burned through nearly $11-12 billion in R&D spend in 2024 while watching its post-COVID revenue cliff steepen, this is not a routine portfolio tightening. It is a strategic confession.

The Weight of Two Bets

Start with what Boshoff is actually saying, stripped of the diplomatic phrasing. Pfizer is retreating to oncology — a space it paid $43 billion to reenter via Seagen in 2023 — and simultaneously making a late charge into obesity pharmacology, a market already being shaped by Novo Nordisk and Eli Lilly with a combined GLP-1 revenue run rate approaching $50 billion annually. Both moves make commercial sense in isolation. Together, they reveal a company that has concluded its mid-tier assets — the infectious disease portfolio extensions, the gene therapy experiments, the hospital products — cannot generate the peak sales multiples that justify the capital required to advance them.

The Seagen acquisition was supposed to be Pfizer’s oncology anchor, delivering ADC (antibody-drug conjugate) platforms — PADCEV, TUKYSA, TIVDAK — as blockbuster-ready assets. But Pfizer’s 2024 full-year results showed oncology revenue of roughly $15.6 billion, still well short of the $20 billion-plus run rate the deal economics demanded at announcement. The Seagen bet needs reinforcement — which explains why Boshoff is publicly reaffirming oncology focus rather than letting the pipeline speak for itself. When a CSO goes on the record in a peer-reviewed journal to discuss therapeutic priorities, that is not science communication. It is investor relations by another channel.

The obesity angle is where the strategic logic gets genuinely complicated. Pfizer has already failed once in this space — its oral GLP-1 candidate danuglipron was discontinued in late 2023 after Phase 2 liver enzyme findings. Re-entering obesity R&D now, against Novo’s semaglutide franchise and Lilly’s tirzepatide-plus-retatrutide pipeline, means competing against two companies with multi-year head starts, established prescriber relationships, and manufacturing scale that Pfizer does not have in this category. But retreat is commercially worse — the obesity market is projected to exceed $100 billion by 2030, and any large-cap pharma without a position in metabolic disease will face a structural revenue gap that no amount of oncology success can fully offset.

The Other Two Signals

Pfizer is not doing this alone, which is what makes Boshoff’s interview a trend marker rather than a company-specific pivot story.

AstraZeneca has been executing the same compression thesis for three years, just more quietly. Its 2024 revenue of $54.1 billion was overwhelmingly concentrated in oncology and rare disease, with CVRM (cardiovascular, renal, metabolism) as the third leg — essentially a two-and-a-half therapeutic area company masquerading as a broad-based pharma. AZ’s BD&L activity reflects this: the $1.5 billion licensing deal for AKT inhibitor capivasertib with its own internal oncology platform, the $2.4 billion acquisition of Fusion Pharmaceuticals for radioligand therapy in early 2024. Every deal sharpens the same two edges. What AZ has quietly shed — respiratory pipeline beyond Symbicort lifecycle, early CNS efforts, broad infectious disease — gets far less press coverage than what it is acquiring.

Then there is Merck, whose situation crystallizes why therapeutic compression is not purely a growth strategy — for some companies, it is a survival response. Keytruda, Merck’s anti-PD-1 blockbuster, faces biosimilar entry beginning in 2028, with 2024 Keytruda revenue of $29.5 billion representing roughly 46% of total company revenue. Merck’s answer has been to concentrate even harder into oncology — acquiring Prometheus Biosciences, licensing belzutifan from its own internal programs, chasing a TIGIT combination strategy — rather than diversify away from the category that built its current valuation. The counterintuitive read: Merck is doubling into the space most threatened by its own patent cliff, betting that oncology pipeline density will outrun biosimilar erosion. Whether that bet pays depends entirely on whether its next-generation IO combinations can clear Phase 3 before the Keytruda revenue line starts compressing.

Three companies. Three different entry points into the same strategic logic: concentrate into oncology, add metabolic/obesity as the second growth vector, exit or de-prioritize everything else. The Great Therapeutic Compression is not a theory — it is already the operating model for companies controlling more than $150 billion in combined annual pharma revenue.

Who Gets Squeezed Out

Here is the assumption Wall Street is making that deserves scrutiny: that therapeutic compression at the top creates acquisition opportunity for mid-caps holding the assets Big Pharma is quietly walking away from. The logic sounds right. In practice, the assets being de-prioritized are de-prioritized for a reason — subcommercial peak sales projections, crowded competitive landscapes, or reimbursement structures that haven’t materialized. When Pfizer trims its hospital business or AstraZeneca lets a CNS program lapse, it is not leaving gold on the table for Royalty Pharma or a mid-cap acquirer to find. It is signaling that the risk-adjusted NPV of those assets failed an internal commercial screen run by people with more data than the public markets have.

The real competitive pressure lands on companies that cannot afford to compress. Bristol Myers Squibb, carrying roughly $47 billion in debt following its Celgene and Karuna acquisitions, does not have the balance sheet flexibility to walk away from mid-tier assets that are servicing that debt load — even as oncology and neuroscience increasingly require focus to compete. BMS’s 2025 guidance implied flat-to-modest revenue growth against a $13 billion debt maturity schedule over the next three years. That is a company being forced to run a broad portfolio not by strategic choice but by financial obligation.

For investors, the compression trend clarifies one underpriced risk and one underpriced opportunity. The risk: single-asset mid-cap biotechs in immunology and infectious disease who assumed Big Pharma BD&L appetites would remain broad. The appetite is narrowing, and the licensing terms are reflecting it. The opportunity: platform companies in oncology and metabolic disease with modality advantages neither Pfizer nor Merck can build quickly internally. Arvinas, whose PROTAC platform addresses targets that ADCs and IO combinations cannot reach, raised $400 million in 2024 specifically because its differentiation survives in a compressed competitive landscape — large pharma cannot replicate the modality on the acquisition timeline it would need to matter.

Pfizer’s Boshoff said the quiet part out loud in March 2026. But the restructuring logic has been visible in deal flow, pipeline pruning, and earnings commentary for at least eighteen months. The companies still building diversified portfolios on the assumption that breadth equals resilience are operating on a model their largest competitors have already discarded. By Q1 2027, the BD&L market will make that gap visible in a way that a Nature Reviews interview cannot soften — because the term sheets will simply stop arriving for the assets that fall outside oncology and metabolic disease. Pfizer will be fine. The mid-caps waiting for Pfizer to call them about their CNS program should start revising their assumptions now.

References

  1. Boshoff, C. “Reshaping Pfizer’s drug discovery priorities.” Nature Reviews Drug Discovery, March 12, 2026.
  2. Pfizer Q4 and Full-Year 2024 Financial Results. Pfizer Inc. Press Release.
  3. Pfizer Completes Acquisition of Seagen. Pfizer Inc. Press Release, 2023.
  4. Pfizer Provides Update on Danuglipron Development Program. Pfizer Inc. Press Release, 2023.
  5. AstraZeneca 2024 Annual Report. AstraZeneca PLC.
  6. Merck 2024 Annual Report. Merck & Co., Inc.
Website |  + posts

Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.